Significance of endothelin-1 in myocardial infarction

Hellenic Journal of Cardiology

Volumn 48, Issue 3, 2007, Pages 161-164

  Antonopoulos, Athanassios ^a,b   Kyriacou, Constandinos ^a   Kazianis, George ^a  

^a 7th IKA Hospital   (Greece)

^b NONE   (Greece)

Author keywords

Endothelin 1; Myocardial infarction; Reperfusion therapy

Indexed keywords

DARUSENTAN; ENDOTHELIN 1; BIOLOGICAL MARKER;

CELL ADHESION; CELL PROLIFERATION; CONGESTIVE HEART FAILURE; CORONARY REPERFUSION; ENDOTHELIUM CELL; HEART INFARCTION; HUMAN; HYPERTENSION; NONHUMAN; PATHOGENESIS; PROGNOSIS; REPERFUSION; REVIEW; BLOOD; CLINICAL TRIAL; HEART MUSCLE REPERFUSION; METABOLISM;

BIOLOGICAL MARKERS; CLINICAL TRIALS; ENDOTHELIN-1; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PROGNOSIS;

EID: 34548044011     PISSN: 10117970     EISSN: 10117970     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Khan IA: Role of endothelin-1 in acute myocardial infarction. Chest 2005; 127: 1474-1476.
2. Berger R, Pacher R: The role of the endothelin system in myocardial infarction: new therapeutic targets. Eur Heart J 2003; 24: 294-296.
3. Spieker L, Noll G, Ruschitzka FT, Luescher TF: Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J Am Coll Cardiol 2001; 37: 1493-1505.
4. MacCarthy PA, Grocott-Mason R, Prendergast BD, et al: Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ET(A) receptor antagonist. Circulation 2000; 101: 142-147.
5. Reimunde F, Castañares C, Redondo-Horcajo M, et al: Endothelin-1 expression is strongly repressed by AU-rich elements in the 3′- untranslated region of the gene. Biochem J 2005; 387(Pt 3): 763-772.
6. Miyauchi T, Masaki T: Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 1999; 61: 391-415.
7. Yamashita K, Discher DJ, Hu J, Bishopric NH, Webster KJ: Molecular regulation of the endothelin-1 gene by hypoxia. Biol Chem 2001; 16: 12645-12653.
8. Lopez Farre A, Riesco A, Espinosa G, et al: Effect of endothelin-1 on neutrophil adhesion to endothelial cells and perfused heart. Circulation 1993; 88: 1166-1171.
9. Knofler R, Urano T, Malyszko J, Takada Y, Takada A: In vitro effect of endothelin-1 on collagen and ADP-induced aggregation in human whole blood and platelet rich plasma. Thromb Res 1995; 77: 69-78.
10. Yamauchi T, Ohnaka K, Takayanagi R, et al: Enhanced secretion of endothelin-1 by elevated glucose levels from cultured bovine endothelial cells. FEBS Lett 1990; 267: 16-18.
11. Yildiz L, Akcay F, Kaynar H, et al: Increased plasma endothelin-1 in heavy and light smokers (letter). Clin Chem 1996; 42: 483-484.
12. Boulanger CM, Tanner FC, Bea ML, et al: Oxidized low-density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res 1992; 70: 1191-1197.
13. Stewart DJ, Kubac G, Costello KB, et al: Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol 1991; 18: 38-43.
14. Tsutamoto T, Wada A, Hayashi M, et al: Relationship between transcardiac gradient of endothelin-1 and left ventricular remodelling in patients with first anterior myocardial infarction. Eur Heart J 2003; 24: 346-355.
15. Kinlay S, Behrendt D, Wainstein M, et al: Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation 2001; 104: 1114-1118.
16. Zeiher AM, Goebel H, Schachinger V, Ihling C: Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation 1995; 91: 941-947.
17. Yip HK, Wu CJ, Chang HW, et al: Prognostic value of circulating levels of endothelin-1 in patients after acute myocardial infarction undergoing primary coronary angioplasty. Chest. 2005; 127: 1491-1497.
18. Omland T, Lie RT, Aakvaag A, et al: Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89: 1573-1579.
19. Rezkalla SH, Kloner RA: No-reflow phenomenon. Circulation 2002; 105: 656- 662
20. Iwakura K, Ito H, Kawano S, et al: Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J Am Coll Cardiol 2001; 38: 472-477.
21. Galiuto L, DeMaria AN, del Balzo U, et al: Ischaemia-reperfusion injury at the microvascular level: treatment by endothelin A-selective antagonist and evaluation by myocardial contrast echocardiography. Circulation 2000; 102: 3111-3116.
22. Niccoli G, Lanza GA, Shaw S, et al: Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization. Eur Heart J 2006; 27: 1793-1798.
23. Brain SD, Tippins JR, Williams TJ: Endothelin induces potent microvascular vasoconstriction. Br J Pharmacol 1988; 95: 1005-1007.
24. Filep JG, Foldes-Filep E, Rousseau A, Fournier A, Sirois P, Yano M: Endothelin-1 enhances vascular permeability in the rat heart through the ETA receptor. Eur J Pharmacol 1992; 219: 343-344.
25. Adlbrecht C, Bonderman D, Plass C, et al: Active endothelin is an important vasoconstrictor in acute coronary thrombi. Thromb Haemost 2007; 97: 642-649.
26. Szabo G, Fazekas L, Bahrle S, et al: Endothelin-A and -B antagonists protect myocardial and endothelial function after ischemia/reperfusion in a rat heart transplantation model. Cardiovasc Res 1998; 39: 683-690.
27. Verma S, Fedak PM, Weisel RD, et al: Fundamentals of reperfusion injury for the clinical cardiologist. Circulation 2002; 105: 2332-2342.
28. Gonon AT, Wang QD, Penrow J: The endothelin A receptor antagonist LU 135252 protects the myocardium from neutrophil injury during ischaemia/reperfusion. Cardiovasc Res 1998; 39: 674-682.
29. Bohm F, Settergren M, Gonon AT, Penrow J: The endothelin-1 receptor antagonist bosentan protects against ischaemia/reperfusion-induced endothelial dysfunction in humans. Clin Sci (Lond) 2005; 108: 357-363.